Clinical Trials Browser

Chromosome 17 deletion, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02756611 2023-04-10

VENICE I

Phase 3 Completed

258 enrolled 27 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03310190 2023-03-30

DEVOTE

Completed

93 enrolled

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02980731 2023-02-22

VENICE II

Phase 3 Completed

210 enrolled 36 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01889186 2021-12-16

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Phase 2 Completed

158 enrolled 21 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03943342 2021-11-05

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00772486 2021-09-22

A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

Phase 1 Completed

13 enrolled

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Immune System Diseases, Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03197259 2021-03-09

CLLTRegistry

Recruiting

1,000 enrolled

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01527045 2020-01-02

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Phase 2 Completed

47 enrolled 18 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Chromosome 17 deletion, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT01392079 2019-10-24

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

Phase 2 Completed

135 enrolled

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01675102 2019-08-16

17p-CLL

Completed

41 enrolled

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01008462 2019-06-11

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Phase 2 Completed

16 enrolled 15 charts

LymphoidOther hematologic neoplasmPlasma cell

Chromosome 17 deletion, Hodgkin Disease, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, B-Cell